Suspension of trading
Valuation SpringWorks Therapeutics, Inc.
Equities
SWTX
US85205L1070
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 46.99 USD | +0.02% |
|
-.--% | +30.06% |
Company Valuation: SpringWorks Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 3,476 | 3,020 | 1,616 | 2,630 | 2,687 | 3,541 |
| Change | - | -13.11% | -46.49% | 62.74% | 2.16% | 31.78% |
| Enterprise Value (EV) | 2,970 | 2,916 | 1,549 | 2,454 | 2,687 | 3,541 |
| Change | - | -1.82% | -46.89% | 58.46% | 9.48% | 31.78% |
| P/E ratio | -69.1x | -17.3x | -4.99x | -7.09x | -10.4x | -31.1x |
| PBR | - | - | - | - | 5.59x | - |
| PEG | - | -0x | -0.1x | 6.16x | 0.3x | 0.5x |
| Capitalization / Revenue | 99.3x | - | - | 483x | 14x | 11x |
| EV / Revenue | 0x | - | - | 0x | 0x | 11x |
| EV / EBITDA | -64.6x | -16.9x | -5.53x | -7.19x | -9.78x | - |
| EV / EBIT | -64.1x | -16.8x | -5.52x | -7.15x | -9.66x | - |
| EV / FCF | -90.5x | -22.5x | -9.02x | -10.7x | -14.9x | - |
| FCF Yield | -0% | -0% | -0% | -0% | -0% | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -1.05 | -3.59 | -5.21 | -5.15 | -3.48 | -1.51 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 35 | - | - | 5.447 | 191.6 | 322.9 |
| EBITDA | -45.98 | -173 | -279.9 | -341.3 | -274.7 | - |
| EBIT | -46.32 | -173.5 | -280.7 | -343 | -278.1 | - |
| Net income | -45.57 | -173.9 | -277.4 | -325.1 | -258.1 | - |
| Net Debt | -505.8 | -104 | -67.49 | -176.1 | - | - |
| Reference price 2 | 72.52 | 61.98 | 26.01 | 36.50 | 36.13 | 46.99 |
| Nbr of stocks (in thousands) | 47,931 | 48,727 | 62,137 | 72,058 | 74,365 | 75,349 |
| Announcement Date | 25/02/21 | 24/02/22 | 28/02/23 | 27/02/24 | 20/02/25 | - |
1USD in Million2
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| -31.12x | - | - | - | 3.54B | ||
| 26.99x | 5.78x | 17.29x | 1.74% | 81.33B | ||
| 18.58x | 3.56x | 10.55x | 0.52% | 57.33B | ||
| 54.26x | 13.05x | 30.99x | -.--% | 53.86B | ||
| 33.32x | 5.03x | 16.65x | 0.81% | 38.73B | ||
| 338.62x | 11.21x | 154.66x | -.--% | 19.4B | ||
| 359.37x | 126.76x | 233.36x | - | 18.86B | ||
| 11.2x | 2.05x | 6.25x | -.--% | 18.31B | ||
| 14.77x | 2.04x | 7.05x | -.--% | 13.14B | ||
| Average | 91.78x | 21.19x | 59.60x | 0.44% | 33.83B | |
| Weighted average by Cap. | 69.32x | 14.10x | 39.65x | 0.72% |
Year-on-year evolution of the PER
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- SWTX Stock
- Valuation SpringWorks Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition